Clinical Trial Update: Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients [Phase 4]

View source ↗

Summary

Phase 4 switch study in HIV-1-infected patients evaluating once-daily atazanavir/ritonavir combined with twice-daily raltegravir; results posted in October 2014…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atazanavir/ritonavir (atazanavir/ritonavir)
• Raltegravir (raltegravir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV, Combination Therapy | Phase 4 | Status: COMPLETED | Results posted: 2014-10-16